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functional significance of MC cover-
age and EC-MC association in tu-
mors? Mere physical proximity does
not guarantee proper molecular inter-
action or microstructural integration
between MCs and ECs. For example,
despite their tight EC-MC association
(4), T241 fibrosarcomas have high
vascular permeability (16). Further-
more, improved MC coverage does
not guarantee normal vascular func-
tion. For example, 80% of the vascular
surface area of the murine mammary
carcinoma MCaIV is covered with
MCs (17), yet these tumor vessels are
profoundly leaky (18). Is it possible
that the tumor vessel–associated MCs
increase the vessel permeability by
expressing VEGF? In addition to con-
trolling vessel function and integrity,
do these perivascular cells lead
endothelial sprouts during angiogen-
esis, as suggested by both intravital
microscopy and immunohistochem-
istry (8, 17)? The present study is an
important step in answering these
urgent questions.
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Toll-like receptors (TLRs) recognize microbial molecular signatures and
can initiate innate immune responses against invading pathogens. A new
study (see the related article beginning on page 1234) reports how TLR2
expression by endothelia is locally upregulated by the action of activat-
ed polymorphonuclear neutrophils via an unprecedented mechanism
involving cell-cell interaction and NAD(P)H oxidase. The report reveals
yet another way in which the primordial innate immune system is
remarkably complex.
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In this issue of the JCI, Fan et al. report
on receptor “cross talk” between mem-
bers of the Toll-like receptor (TLR)
family (1). This elegant study confirms
previous observations that inflamma-
tion via TLR4 results in the enhanced
expression of TLR2 (2, 3). However,
Fan et al. elucidate a new mechanism
of enhancement of endothelial TLR2
expression that may have important
physiological consequences. Polymor-
phonuclear neutrophils (PMNs) that
have been activated by endotoxin (LPS)
can instruct endothelia to upregulate
TLR2 and thus sensitize endothelia to
TLR2 ligands. This message is sent to
endothelial cells by the release of free
oxygen radicals as the result of a CD18-
dependent cell-cell interaction. TLR2
expression in endothelium, for exam-
ple, was dramatically enhanced when
endothelium was co-incubated with
activated PMN from normal mice but
not mice with a targeted lesion in
gp91phox, a member of the NAD(P)H oxi-
dase complex. The enhanced TLR2
expression was demonstrated to result
in subsequently enhanced responses to
peptidoglycan, a TLR2 ligand. The abil-
ity of LPS to sensitize endothelial cells
for TLR2 stimuli via LPS-induced acti-
vation of PMNs represents a previous-
ly unsuspected positive feedback loop.
What distinguishes this paper by Fan
et al. from a large number of reports
that purport to demonstrate receptor
cross talk” in the innate immune sys-
tem is that the authors go on to de-
monstrate that the relationship among
TLR4, TLR2, and the oxidative machin-
ery has functional consequences. Dur-
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ing the course of experimental Gram-
negative infection, the absence of this
enhanced TLR2 expression led to a
blunted response to bacterial chal-
lenge: the influx of PMNs into infected
lung was reduced by nearly 60% in
TLR2 knockout mice.
In the last few years, it has become
commonplace to refer to the complex
physiological loops in immunity
using phrases such as “immunologi-
cal cross talk” and “immunological
synapse,” as if we are surprised by
their existence. Indeed, when TLRs
were first discovered — and it became
clear that TLR4 was a receptor for
LPS while TLR2 recognized purified
peptidoglycan, lipoteichoic acids, and
other Gram-positive bacterial prod-
ucts — the simplistic notion that
TLR2 was a Gram-positive receptor
and TLR4 a Gram-negative receptor
evolved into dogma (4–9). This
dogma (to which we, unfortunately,
contributed) has now been shattered
by the observation by Fan et al. (1)
that the TLR2 KO mouse has a clear
phenotype with respect to Gram-neg-
ative infections. It is time to shake
ourselves free of the concept that the
TLR family is individually devoted to
single classes of microorganisms.
Rather, TLRs are devoted to definable
ligands and were designed through
the nearly perfect hand of evolution
to work in a concerted effort to pro-
tect the host from infection.
A mechanism to enhance local
inflammatory responses
Perhaps the most instructive aspect of
the study by Fan et al. (1) is not simply
the upregulation of TLR2 in response
to LPS, nor the fact that this process is
mediated by a product of the oxidative
burst (functioning like a cytokine), but
the implication that these processes are
so perfectly coordinated temporally.
When one considers the interactions of
the innate immune system as microbes
are first encountered, the value of such
temporal organization is great. Con-
sider the numerous studies over the
years that have demonstrated how the
interaction of whole Gram-negative
bacteria with immune effector cells is
similar to the interaction of LPS with
these cells. These studies are instructive
but fall far short of teaching us how
the host responds to real infection.
Unlike LPS, Gram-negative bacteria
persist in tissues and — if not immedi-
ately killed through the actions of
PMNs, complement, and other antimi-
crobial factors — may invade the host.
Survival depends upon the innate
immune system, which must be able to
monitor and respond to pathogens
over a prolonged period of time.
Because of the need for a prolonged
response to bacterial infection, it has
always seemed somewhat surprising
that responses to LPS have a finite
time limit. This time-limited response
of the innate immune system to the
presence of Gram-negative bacterial
endotoxin, known as tolerance, means
that within hours after exposure to
LPS, innate immune cells are inca-
pable of responding again to re-chal-
lenge (10). But it is now clear that as
LPS sensitivity wanes, the immune sys-
tem has at its disposal the capability of
marshaling responses via oxidative
metabolites and their ability to upreg-
ulate other TLRs. The subsequent
means of responding to bacteria
depend upon the ability of the innate
immune system to destroy microbes
and enhance the release of alternative
immune stimuli. The TLRs that are
utilized are the ones that bind the con-
stituents of degrading bacteria, such as
lipopeptides, peptidoglycan, heat
shock proteins, and 2′-deoxyribo(cyti-
dine-phosphate-guanosine)–rich
(CpG-rich) DNA. It seems plausible
that activated PMNs may even alter
the phenomenon of LPS tolerance, at
least in a localized context, by setting
into action a positive feedback loop at
sites to which PMNs are chemotacti-
cally attracted (normally the site of
infectious challenge). This would
locally enhance inflammatory respons-
es needed to fight infection while
reducing the general responsiveness of
endothelia in noninfected areas of the
host. Finally, this complex process of
temporally regulated responses to
microbes via different TLRs is unlike-
ly to be restricted to bacteria. Recent
studies, for example, have document-
ed the recognition of herpes viruses by
TLR2 (11). As these viruses uncoat
and replicate, it is likely that their
DNA also encounters TLR9, as recent-
ly described for herpes simplex virus 2
(12). The general theme is that, as
pathogens march through their target
cells, a highly coordinated and intri-
cate immune response program is
likely initiated.
The message, quite simply, is that
innate immunity is not simple. What
began as the study of fruit flies and
caterpillars has become the basis of
our hopes for new cures for diseases as
lethal as sepsis and systemic lupus ery-
thematosus. While most investigators
choose to simplify their in vitro mod-
els of disease, it is the complex experi-
ments, such as those of Fan et al. (1),
that best reveal how biology functions
outside of the test tube.
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